HEALTHCARE

Credit Suisse has now lowered the price to $14 per share from $18, having cut the price from $20 just three weeks ago.

The workers in the Yeruham plant will also receive bonuses and pay hikes under the agreement signed with Perrigo's management.

Happify combines digital therapeutics with drug treatment.

The test provides a new dimension of genetic insight with comprehensive health reports that can empower future health and lifestyle choices.

BioProtect's product protects healthy tissue from radiation during cancer treatment.

Deputy Minister of Health Yaakov Litzman announced that a license would no longer be required to use cannabis for certain indications.

The life sciences venture capital fund could become the controlling shareholder in universal flu vaccine developer Biondvax after the company's rights issue.

The Israeli company has developed two products: a heart diagnostic device connected to a smartphone and a sticker for monitoring patients in hospital beds

S&P Global is not changing its rating for Teva's debt at present.

With 43 million shares in the Israeli pharmaceutical company, Berkshire Hathaway has lost $283 million on its Teva stake this year.

Kare Schultz received millions of dollars of blocked shares, which he will receive if the share price reaches a certain level by November 2020.

HSBC estimates Teva will face a $3 billion fine and has cut the Israeli pharmaceutical company's share target price to $10.

By implanting engineered tissue from stem cells taken from the gums, the Technion's Prof. Shulamit Levenberg provides new hope for people with spinal column injuries.

A judge in Oklahoma rejected an attempt by Teva and Johnson & Johnson to have charges against them dismissed.

The investment is in stock exchange shell Herodium, into which cannabis company Panaxia Israel will be merged.

Check Cap's C-Scan system is an ingestible capsule for the detection of precancerous polyps.

Assuming it obtains all of the necessary permits, Cannabit's revenue from the agreement will be NIS 30 million.

Speaking at an Oppenheimer conference, Teva's Mike McClellan said the price-fixing allegations in the US were not new, and went on to describe the company's growth engines.

44 US states have filed a lawsuit alleging that Teva conspired with other companies to raise prices of generic drugs by as much as 1,000%.

Prof. Irad Ben-Gal talks to "Globes" about dual digital and physical existence, and other ways technology will challenge our present assumptions about human life.

At 55, Dr. Anda Baharav left her work as a pediatrician to found a startup that provides personalized treatment for sleep disorders.

Having 3D printed a heart, Tel Aviv University's Prof. Tal Dvir says in principle, he can regenerate any organ in the body.

Transport, energy and healthcare are three areas where big decisions loom, and determination will be needed to carry them out.

"Globes" examines what the pioneering medical cannabis reform, due to come into effect after the election, will mean for patients, doctors, and all concerned.